Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
Burton
Dennis R
DR
Scripps Research Institute, La Jolla, California, USA.
Desrosiers
Ronald C
RC
Doms
Robert W
RW
Feinberg
Mark B
MB
Gallo
Robert C
RC
Hahn
Beatrice
B
Hoxie
James A
JA
Hunter
Eric
E
Korber
Bette
B
Landay
Alan
A
Lederman
Michael M
MM
Lieberman
Judy
J
McCune
Joseph M
JM
Moore
John P
JP
Nathanson
Neal
N
Picker
Louis
L
Richman
Douglas
D
Rinaldo
Charles
C
Stevenson
Mario
M
Watkins
David I
DI
Wolinsky
Steven M
SM
Zack
Jerome A
JA
D016915:AIDS Vaccines / Q000276:immunology*; D017326:Clinical Trials, Phase III as Topic / Q000191:economics; D003365:Costs and Cost Analysis; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D013785:Thailand; D014481:United States; D014614:Vaccines, Synthetic / Q000276:immunology
D016915:AIDS Vaccines; D015699:HIV Envelope Protein gp120; D014614:Vaccines, Synthetic